Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Polaprezinc for ESD-induced gastric ulcer healing
NCT02243618Completed
- Sponsor
- Yonsei University
- Start
- Jan 2015
- Primary completion
- Apr 2016
- Modality
- Peptides, Orthosteric Ligands
- Countries
- 1
01
Overview
Randomised, open-label trial of polaprezinc in Peptic ulcer disease (PUD), sponsored by Yonsei University. Primary endpoint: Ulcer healing rate at 4 weeks. Started Jan 2015; status: completed.
02
Drugs
polaprezinc
03
Conditions
Peptic ulcer disease (PUD)
Beyond the preview
Go deeper on NCT02243618.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02243618.